Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Temozolomide + Low-dose Radiotherapy in Recurrent Glioblastoma
NCT06220552Phase 2Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in glioblastoma (GBM), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 1 year. Started Dec 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06220552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220552.